iifl-logo-icon 1

Divis Laboratories Ltd Share Price

4,591.3
(1.15%)
Jul 15, 2024|12:49:59 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Equities

Futures

Option

  • Open4,542
  • Day's High4,596.75
  • 52 Wk High4,670
  • Prev. Close4,539.3
  • Day's Low4,536.1
  • 52 Wk Low3,295.3
  • Turnover (lac)18,404.31
  • P/E76.44
  • Face Value2
  • Book Value537.97
  • EPS59.37
  • Mkt. Cap (Cr.)1,21,884.59
  • Div. Yield0.66
Loading...
  • Open4,561.15
  • Day's High4,612
  • Spot4,587
  • Prev. Close4,550.95
  • Day's Low4,545
  • ViewShort Covering
  • Market Lot200
  • OI(Chg %)-30,000 (-1.13%)
  • Roll Over%0.41
  • Roll Cost0.39
  • Traded Vol.4,85,200 (-65.7%)
View More Futures

Divis Laboratories Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

4,542

Prev. Close

4,539.3

Turnover(Lac.)

18,404.31

Day's High

4,596.75

Day's Low

4,536.1

52 Week's High

4,670

52 Week's Low

3,295.3

Book Value

537.97

Face Value

2

Mkt Cap (₹ Cr.)

1,21,884.59

P/E

76.44

EPS

59.37

Divi. Yield

0.66

Divis Laboratories Ltd Corporate Action

3 Jul 2023

12:00 AM

AGM

Announcement Date: 03 Jul, 2023

arrow

20 May 2023

12:00 AM

Dividend

Dividend Amount: 30

Record Date: 11 Aug, 2023

arrow

15 May 2024

12:00 AM

Board Meeting

Agenda : Audited Result

arrow

Divis Laboratories Ltd NEWS AND UPDATE

No data found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Divis Laboratories Ltd SHAREHOLDING SNAPSHOT

15 Jul, 2024|01:11 PM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 51.92%

Foreign: 0.00%

Indian: 51.92%

Non-Promoter- 36.89%

Institutions: 36.89%

Non-Institutions: 11.18%

Custodian: 0.00%

Share Price

Divis Laboratories Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Loading...
Y/e 31 Mar( In .Cr)Mar-2023Mar-2022Mar-2021Mar-2020

Equity Capital

53.09

53.09

53.09

53.09

Preference Capital

0

0

0

0

Reserves

12,652.33

11,638.26

9,218.48

7,263.6

Net Worth

12,705.42

11,691.35

9,271.57

7,316.69

Minority Interest

View Balance Sheet
Loading...
Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2018

Revenue

8,879.82

6,798.61

5,310.57

3,815.94

yoy growth (%)

30.61

28.02

39.16

-5.16

Raw materials

-2,989.8

-2,265.5

-2,088.56

-1,504.9

As % of sales

33.66

33.32

39.32

39.43

Employee costs

-926.55

-808.68

-608.36

-446.27

View Profit & Loss
Loading...
Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2018

Profit before tax

3,676.52

2,627.87

1,813.29

1,219.36

Depreciation

-310.55

-254.65

-185.95

-142.42

Tax paid

-727.98

-673.15

-440.58

-349.78

Working capital

2,090.79

2,216.26

733.27

298.91

Other operating items

View Cash Flow
Loading...
Y/e 31 MarMar-2022Mar-2021Mar-2020Mar-2018

Growth matrix (%)

Revenue growth

30.61

28.02

39.16

-5.16

Op profit growth

37.42

55.37

45.16

-13.01

EBIT growth

39.89

44.47

49.04

-12.21

Net profit growth

50.84

42.39

57.85

-17.43

View Ratios
Particulars (Rupees in Crores.)Mar-2024Mar-2023Mar-2022Mar-2021Mar-2020

Gross Sales

7,845

7,767

8,959.83

6,969.4

5,394.42

Excise Duty

0

0

0

0

0

Net Sales

7,845

7,767

8,959.83

6,969.4

5,394.42

Other Operating Income

0

0

0

0

0

Other Income

339

345

113.87

62.56

189.63

Divis Laboratories Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceuticals Industries Ltd

SUNPHARMA

1,577.3

124.083,78,675.04867.60.865,536.9998.75

Cipla Ltd

CIPLA

1,512.05

32.871,22,092.681,038.40.563,444.92346.41

Divis Laboratories Ltd

DIVISLAB

4,539.3

76.441,20,480.265310.662,259507.93

Zydus Lifesciences Ltd

ZYDUSLIFE

1,175.15

34.281,18,217.41,405.20.263,172.6156.19

Dr Reddys Laboratories Ltd

DRREDDY

6,719.45

26.171,12,137.091,034.80.595,081.81,458.96

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Divis Laboratories Ltd

Management

Register Office

Registrar Office

Chairman & Managing Director

Murali K Divi

Executive Director

N V Ramana

Whole Time Director (Projects)

Madhusudana Rao Divi

Whole Time Director & CEO

Kiran S Divi

Independent Director

G Suresh Kumar

Independent Director

Ranga Rao Ravipati

Independent Director

K V K Seshavataram

Chairman(Non Exe)&Director(Ind

Ramesh B V Nimmagadda

Whole Time Director -Commercia

Nilima Motaparti

Independent Director

S Ganapaty

Independent Director

Sunaina Singh

Independent Director

Kosaraju Veerayya Chowdary

Company Sec. & Compli. Officer

Satish Choudhury

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Summary

Divis Laboratories Ltd. is one of the leading pharmaceutical companies in the world, manufacturing Active Pharmaceutical Ingredients (APIs), Intermediates and Nutraceuticals. The Company is one of the worlds largest API companies, with two manufacturing units and a market presence across 100 countries. It is engaged in the manufacture of Active Pharmaceutical ingredients (APIs), Intermediates and Nutraceutical ingredients with predominance in exports. In addition to generic business, the Company, through its custom synthesis business, supports innovator pharma companies for their patented products business right from gram scale requirements for clinical trials to launch as well as late life cycle management. It is among the largest pharmaceutical companies in India with a portfolio of approx. 160 products across diverse therapeutic areas. Presently, it has 6 manufacturing facilities and market presence across several countries. The company has two subsidiaries M/s. Divis Laboratories (USA) Inc., in the United States of America and M/s. Divis Laboratories Europe AG in Switzerland for marketing its Nutra products and to provide a greater reach to customers within these regions. The company has Research Centers at Sanathnagar, Hyderabad and at the manufacturing sites. Research Centre at Sanathnagar primarily focuses on custom synthesis, contract research for MNC companies as also future generics involving processes like route design, route selection, establishing gram scale proc
Read More

Company FAQs

What is the Divis Laboratories Ltd share price today?

Down Arrow

The Divis Laboratories Ltd shares price on N/A is Rs.₹4590.75 today.

What is the Market Cap of Divis Laboratories Ltd?

Down Arrow

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Divis Laboratories Ltd is ₹121869.99 Cr. as of 15 Jul ‘24

What is the PE and PB ratio of Divis Laboratories Ltd?

Down Arrow

The PE and PB ratios of Divis Laboratories Ltd is 76.44 and 8.93 as of 15 Jul ‘24

What is the 52 Week High and Low of Divis Laboratories Ltd?

Down Arrow

The 52-week high/low is the highest and lowest price at which a Divis Laboratories Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Divis Laboratories Ltd is ₹3300 and ₹4670.2 as of 15 Jul ‘24

What is the CAGR of Divis Laboratories Ltd?

Down Arrow

Divis Laboratories Ltd's CAGR for 5 Years at 23.01%, 3 Years at -0.36%, 1 Year at 24.91%, 6 Month at 16.88%, 3 Month at 20.09% and 1 Month at 2.02%.

What is the shareholding pattern of Divis Laboratories Ltd?

Down Arrow

The shareholding pattern of Divis Laboratories Ltd is as follows:
Promoters - 51.92 %
Institutions - 36.89 %
Public - 11.19 %

Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.